CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Maintains Target Price $93
CCORF analyst Whitney Ijem maintains $Biomarin Pharmaceutical(BMRN.US)$ with a hold rating, and maintains the target price at $93.According to TipRanks data, the analyst has a success rate of 51.3%
A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $72 to $115
On Sep 18, major Wall Street analysts update their ratings for $Biomarin Pharmaceutical(BMRN.US)$, with price targets ranging from $72 to $115.Barclays analyst Gena Wang maintains with a buy rating,
Hold Rating on BioMarin Pharmaceutical Amid Competitive Dynamics and Market Penetration Nuances for Voxzogo
BioMarin To Present Positive VOXZOGO (Vosoritide) Data From CANOPY Clinical Program At 2024 International Skeletal Dysplasia Society Meeting
BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO (Vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children With Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting
BioMarin Pharmaceutical Price Target Cut to $90.00/Share From $115.00 by Wells Fargo
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $78 to $122
On Sep 17, major Wall Street analysts update their ratings for $Biomarin Pharmaceutical(BMRN.US)$, with price targets ranging from $78 to $122.Barclays analyst Gena Wang maintains with a buy rating,
BioMarin Pharmaceutical Is Maintained at Buy by Stifel
Bernstein Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $90
BioMarin Pharmaceutical (BMRN) Receives a Buy From Truist Financial
RBC Cuts Price Target on BioMarin Pharmaceutical to $85 From $100, Keeps Sector Perform Rating
Express News | Biomarin Pharmaceutical Inc : Jefferies Cuts Target Price to $122 From $126
Trending Stocks Today | NuCana Shoots up 161.02%
September 16th - US stocks trending in regular trading hours.Gainers: $NuCana(NCNA.US)$ surges 161.02% to $6.63 with a turnover of $331.35 million. $Bone Biologics(BBLG.US)$ soars 107.5% to $1.66
Express News | Biomarin Pharmaceutical Shares Fall 15.3% After Positive Trial Data for Rival Ascendis Pharma's Dwarfism Therapy
BioMarin Pharmaceutical Down Over 12%, on Pace for Largest Percent Decrease Since August 2020 -- Data Talk
S&P 500 Futures Flat In Premarket Trading; Nuvalent, Bausch + Lomb Lead
Barclays Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $110
Barclays analyst Gena Wang maintains $Biomarin Pharmaceutical(BMRN.US)$ with a buy rating, and maintains the target price at $110.According to TipRanks data, the analyst has a success rate of 44.7%
Barclays Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical Is Maintained at Hold by Canaccord Genuity